ES2139012T3 - Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana. - Google Patents

Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.

Info

Publication number
ES2139012T3
ES2139012T3 ES93913627T ES93913627T ES2139012T3 ES 2139012 T3 ES2139012 T3 ES 2139012T3 ES 93913627 T ES93913627 T ES 93913627T ES 93913627 T ES93913627 T ES 93913627T ES 2139012 T3 ES2139012 T3 ES 2139012T3
Authority
ES
Spain
Prior art keywords
human
lymphocytes
specific
cytotoxic
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93913627T
Other languages
English (en)
Inventor
Cornelis Joseph Maria Melief
Wybe Martin Kast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Leiden
Seed Capital Investments (SCI) BV
Original Assignee
Universiteit Leiden
Seed Capital Investments (SCI) BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Leiden, Seed Capital Investments (SCI) BV filed Critical Universiteit Leiden
Application granted granted Critical
Publication of ES2139012T3 publication Critical patent/ES2139012T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

UN PEPTIDO QUE COMPRENDE UNA SECUENCIA DE ACIDO AMINO DERIVADA DE LA PROTEINA P53 HUMANA, DE ACIDO AMINO, TIENE LA CAPACIDAD DE ENLAZAR A LA MOLECULA HUMANA CLASE I MHC. SU EMPLEO EN TRATAMIENTOS PROFILACTICOS O TERAPEUTICOS DE ENFERMEDADES TALES COMO LOS CANCERES HUMANOS QUE MUESTRAN UNA SOBRE-EXPRESION DE PROTEINA P53, Y SU EMPLEO EN LA INDUCCION DE CELULAS T ESPECIFICAS P53 PRIMARIAS QUE SE PUEDEN EMPLEAR EN TRATAMIENTOS TERAPEUTICOS. SU USO EN PRUEBAS Y TEST DE DIAGNOSTICO.
ES93913627T 1992-05-26 1993-05-18 Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana. Expired - Lifetime ES2139012T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92201510 1992-05-26

Publications (1)

Publication Number Publication Date
ES2139012T3 true ES2139012T3 (es) 2000-02-01

Family

ID=8210629

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93913627T Expired - Lifetime ES2139012T3 (es) 1992-05-26 1993-05-18 Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.

Country Status (11)

Country Link
US (1) US5679641A (es)
EP (1) EP0643726B1 (es)
JP (2) JPH08501280A (es)
AT (1) ATE183514T1 (es)
AU (1) AU681853B2 (es)
CA (1) CA2136624A1 (es)
DE (1) DE69326064T2 (es)
DK (1) DK0643726T3 (es)
ES (1) ES2139012T3 (es)
GR (1) GR3031919T3 (es)
WO (1) WO1993024525A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002167A1 (en) * 1992-07-22 1994-02-03 The Trustees Of Princeton University p53 VACCINE
FR2698367B1 (fr) * 1992-11-02 1995-02-17 Eurobio Lab Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques.
CN1118572A (zh) * 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
WO1995004817A1 (en) * 1993-08-06 1995-02-16 Cytel Corporation Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
FR2722207B1 (fr) * 1994-07-07 1996-09-27 Inst Nat Sante Rech Med Methode pour generer une population de cellules presentant a leur surface une forte densite d'un pepride exogene specifique associe azx molecules du cmh; population de cellules
EP0793501A4 (en) * 1994-12-14 2000-05-03 Scripps Research Inst IN VIVO ACTIVATION OF TUMOR SPECIFIC CYTOTOXIC T CELLS
US5925799A (en) * 1996-03-12 1999-07-20 Abb Lummus Global Inc. Catalytic distillation and hydrogenation of heavy unsaturates in an olefins plant
NZ331688A (en) * 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
SE9604581D0 (sv) * 1996-12-12 1996-12-12 Karolinska Innovations Ab An agent against cancer and virus infections
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
CA2321026A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE9801695D0 (sv) * 1998-05-14 1998-05-14 Karolinska Innovations Ab Inhibition of p53 function by a p53-derived peptide
ATE429247T1 (de) * 1998-06-17 2009-05-15 Idm Pharma Inc Hla-bindende peptide und ihre verwendungen
AU3755800A (en) * 1999-03-15 2000-10-04 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
TW410377B (en) * 1999-06-17 2000-11-01 Taiwan Semiconductor Mfg Method of planarization and the apparatus of the same
DE60030450T2 (de) * 1999-09-08 2007-08-30 Transgene S.A. Von MUC-1 abgeleitete Peptide
FR2794368A1 (fr) * 1999-10-07 2000-12-08 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
WO2001041788A1 (en) * 1999-12-10 2001-06-14 Epimmune, Inc. INDUCING CELLULAR IMMUNE RESPONSES TO p53 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
AU2001275246B2 (en) * 2000-06-05 2006-06-29 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use thereof
DE10109855A1 (de) * 2001-03-01 2002-09-12 Stanislawski Thomas Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
CA2487779C (en) * 2001-06-05 2012-10-02 Altor Bioscience Corporation P53 binding t cell receptor molecules and uses thereof
WO2003006043A1 (en) 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
JP5068931B2 (ja) * 2002-07-12 2012-11-07 ザ ジョンズ ホプキンス ユニバーシティー 独自のクローン形質のリンパ球受容体に結合する試薬および方法
EP1888105A2 (en) * 2005-05-12 2008-02-20 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
AU2006289683A1 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as T cell receptor mimics, methods of production and uses thereof
WO2008021160A2 (en) * 2006-08-17 2008-02-21 Trustees Of Boston University Regulation of litaf modulated cytokine production by a novel p53 short peptide
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
CA3080274A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US12453774B2 (en) 2019-11-07 2025-10-28 Genoimmune Therapeutics Co., Ltd. Tumor immunotherapy polypeptide and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet

Also Published As

Publication number Publication date
EP0643726A1 (en) 1995-03-22
JPH08501280A (ja) 1996-02-13
EP0643726B1 (en) 1999-08-18
WO1993024525A1 (en) 1993-12-09
DK0643726T3 (da) 2000-03-20
ATE183514T1 (de) 1999-09-15
CA2136624A1 (en) 1993-12-09
AU4359193A (en) 1993-12-30
DE69326064D1 (de) 1999-09-23
DE69326064T2 (de) 2000-05-25
AU681853B2 (en) 1997-09-11
GR3031919T3 (en) 2000-03-31
JP2004123708A (ja) 2004-04-22
US5679641A (en) 1997-10-21

Similar Documents

Publication Publication Date Title
ES2139012T3 (es) Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
ES2075050T3 (es) Peptidos que tienen actividad cooperadora de celulas t.
ES2205132T3 (es) Subunidad catalitica de la telomerasa humana.
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
ATE221125T1 (de) Klonierte glutaminsäure-decarboxylase
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
ATE126441T1 (de) Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen.
EA199800946A1 (ru) Концентрированный препарат антител
ES2091916T3 (es) Metodo para suministrar moleculas en el interior de celulas eucarioticas.
EA199900486A1 (ru) Применение сфингомиелиназы для повышения уровней церамидов в коже и слизистых оболочках, а также содержащие ее дерматологические и косметические композиции, которые удобны для местного применения
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
ATE235510T1 (de) Integrinbindendes peptid und dessen verwendung
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
DE69434384D1 (de) Metalkomplexbildner
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
MX9702666A (es) Nuevos peptidos con efectos inmunoreguladores.
TR199802537T2 (xx) Peptit t�revleri.
GR1000850B (el) Διαλυτα ανθρωπινα τεμαχια cd4 και οι χρησεις τους.
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DE3878231D1 (de) Neues cadiodilatin-fragment, prozess zu dessen herstellung und dessen anwendung.
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
DK199881A (da) Analogifremgangsmaade til fremstilling af pharmakologisk aktive peptider
TR199801769T2 (xx) D���k reg�lasyona diren�li C3 d�n��t�r�c�ler.
AR014647A1 (es) Un polipeptido lipl32 de proteina de membrana externa leptoespiral, un polinucleotido aislado, un vector de expresion, una celula huesped, un metodopara producir dicho polipeptido lipl32, uso de dicho polipeptido para la manufactura de un medicamento, un anticuerpo, una composicion farmaceutica,
BR0012704A (pt) Anticorpos antitumor, proteìnas e usos dos mesmos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 643726

Country of ref document: ES